Skip to main content

Table 4 Free fatty acid composition of HCV patients (pre and post) in comparison of controls

From: A comparative study of serum lipid contents in pre and post IFN-alpha treated acute hepatitis C patients

Free fatty acids

Controls

HCV pretreatment patients

HCV post treatment patients

C – 14:0

1.5 ± 0.6

2.0 ± 1.1

2.0 ± 0.5

C - 16 : 0

23.8 ± 3.6a

28.6 ± 5.9b

25.8 ± 2.5c

C - 18 : 0

10.8 ± 4.1a

14.4 ± 5.4b

10.2 ± 1.7a

C - 20 : 0

0.5 ± 0.9

0.6 ± 2.1

1.6 ± 1.1

C - 14 : 1

0.1 ± 0.3a

NDb

0.2 ± 0.4c

C - 16 : 1

2.8 ± 1.4

3.5 ± 1.5

3.8 ± 1.2

C - 18 : 1

20.7 ± 2.9

19.9 ± 3.9

21.6 ± 2.1

C - 22 : 1

2.2 ± 1.3

2.2 ± 1.3

2.8 ± 1.0

C - 18 : 2

29.9 ± 4.6a

21.2 ± 4.6b

23.8 ± 5.6c

C - 18 : 3

0.4 ± 1.1

0.2 ± 0.6

0.4 ± 0.7

C - 20 : 4

6.1 ± 1.6a

4.4 ± 1.4b

5.3 ± 0.9c

C - 20 : 5

1.0 ± 1.6a

0.4 ± 0.9b

NDc

C - 20 : 3

0.2 ± 0.7

0.1 ± 0.5

0.5 ± 1.3

  1. Values represent mean ± Standard deviation of triplicates. Different alphabets on the same row indicate significant difference at p < 0.05
  2. Myristic acid (C14:0), myristoleic acid (C14:1), palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid (C18:2), α-linolenic acid (C18:3), arachidic acid (C20:0), eicosatrienoic acid (C-20:3), arachidonic acid (C20:4), eicosapentaenoic acid (EPA (C20:5), docosenoic acid (C22:1), docosahexaenoic acid (DHA (C22:6), nervonic acid(C24:1), not detected (ND)